Biogen, Inc. (BIIB) will report second-quarter 2020 results on Jul 22, before the market open. In the last reported quarter, the company delivered an earnings surprise of 18.09%.
The company’s performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. The company has a four-quarter earnings surprise of 13.45%, on average.
Factors to Consider:
Second-quarter revenues are expected to have been adversely impacted by the absence of the first-quarter benefits. Notably, in the first quarter, MS revenues, excluding Ocrevus royalties, rose over year. First-quarter product sales had benefited from accelerated sales as people stocked up medicines amid coronavirus-led lockdown, primarily in Europe.
Biogen receives royalties on U.S. sales of Roche’s newly launched MS drug, Ocrevus which is likely to have contributed to the top line. The Zacks Consensus Estimate for Ocrevus royalties is $198 million.
Among the MS drugs, Tecfidera’s revenues are likely to have been supported by global patient growth. Sales of another MS drug, Tysabri may have risen though partly offset by the impact of Ocrevus launch.
The Zacks Consensus Estimate for sales of Tecfidera is pegged at $1.11 billion while that for Tysabri is $444 million.
Vumerity, launched in the United States late in 2019, recorded sequentially lower sales in the first quarter. It remains to be seen if sales have improved in the second quarter.
Spinraza’s new patient starts and regimen compliance may have declined in the United States in the second quarter, particularly among adults due to COVID-19. Outside the United States, the company expects a moderate impact on Spinraza’s demand due to COVID-19. The Zacks Consensus Estimate for sales of Spinraza is $518 million.
Tecfidera’s sales are unlikely to have been significantly affected due to COVID-19 in the second quarter as the majority of Tecfidera prescriptions in the United States are delivered via mail. However, sales of Tysabri and Spinraza are expected to have been hurt by COVID-19 in the second quarter as they are administered in a physician’s office or hospital setting. This means hospitals may have delayed Tysabri and Spinraza infusions while prioritizing treatment of COVID-19 patients or patients may have chosen to delay treatment.
Interestingly, biosimilars have contributed significantly to Biogen’s top line in the past few quarters driven mainly by Imraldi’s launch, a trend that most likely continued in the second quarter.
Investors will look for updates from management on any delay in supply and manufacturing or timeline of some clinical studies due to potential disruptions from the COVID-19 pandemic when the company reports.
Key Recent Development:
Earlier this month, Biogen completed the submission of the biologics license application (BLA) to the FDA, seeking approval of aducanumab for Alzheimer’s disease. The completed BLA filing includes data from the ENGAGE and EMERGE phase III studies as well as the phase Ib PRIME study in patients with early-stage Alzheimer’s disease. The FDA will now decide within 60 days whether to accept the application for review and also grant its priority review status if accepted.
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.